➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Johnson and Johnson
AstraZeneca
McKesson
Harvard Business School

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

VIIBRYD Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Allergan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in twenty-nine countries.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

Drug patent expirations by year for VIIBRYD
Drug Prices for VIIBRYD

See drug prices for VIIBRYD

Drug Sales Revenue Trends for VIIBRYD

See drug sales revenues for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Forest LaboratoriesPhase 1
New York State Psychiatric InstitutePhase 4
Forest LaboratoriesPhase 3

See all VIIBRYD clinical trials

Recent Litigation for VIIBRYD

Identify potential future generic entrants

District Court Litigation
Case NameDate
Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.2015-11-23
Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.2015-03-30
Forest Laboratories LLC v. Accord Healthcare Inc.2015-03-27

See all VIIBRYD litigation

PTAB Litigation
PetitionerDate
2018-01-05

See all VIIBRYD litigation

Synonyms for VIIBRYD
1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride
1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride
1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride
163521-08-2
2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1)
2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride
2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1)
2794AH
4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride
5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride
5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride
5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride
5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride
5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride
5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride
5-{4-[4-(5-Cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboximidic acid--hydrogen chloride (1/1)
521V128
A3919
AB0000947
AC-25885
AK161007
AKOS024464039
API0009252
AS-74699
AX8294006
BCP11496
C26H27N5O2.ClH
CCG-213313
CHEBI:70705
CHEMBL1615374
CS-0549
D09699
DTXSID80936833
EBD2199528
EMD 68 843
EMD 68843
EMD 68843;SB659746A
EMD-68843
HY-14261
J-525160
KS-00000SKE
LS-34922
Q27139037
RPZBRGFNBNQSOP-UHFFFAOYSA-N
s4259
SB 659746A
SB-659746-A
SB-659746A
SB659746-A
SB659746A
SCHEMBL867358
ST24050347
SW219887-1
U8HTX2GK8J
UNII-U8HTX2GK8J
Viibryd (TN)
Vilazodone (Hydrochloride)
Vilazodone HCl
Vilazodone hydrochloride
Vilazodone hydrochloride (USAN)
Vilazodone hydrochloride [USAN]
Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Vilazodone hydrochloride, >=98% (HPLC)
vilazodone monohydrochloride
vilazodone-hcl
Vilazodonei
Paragraph IV (Patent) Challenges for VIIBRYD
Tradename Dosage Ingredient NDA Submissiondate
VIIBRYD TABLET;ORAL vilazodone hydrochloride 022567 2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011   Start Trial   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011   Start Trial   Start Trial
Allergan VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Johnson and Johnson
AstraZeneca
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.